摘要
目的基于TCGA数据库分析肝癌EFNA3在临床表达的意义。方法采用Wilcoxon signed-rank检验分析EFNA3与临床病理变量的关系。运用Kaplan-Meier方法分析EFNA3表达与肝癌患者总生存期(overall survival,OS)的关系。结果①肝癌患者EFNA3的表达明显高于正常人。②肝癌EFNA3的表达与肿瘤的分级(P=0.003),原发灶大小(P=0.006),肿瘤血管的类型(P=0.024),癌旁组织炎症的程度(P<0.05)均存在明显统计学意义。而EFNA3的表达与年龄,性别,淋巴结转移与远处转移无明显统计学意义。③Kaplan-Meier生存分析显示EFNA3的表达与肝癌患者的预后呈负相关,EFNA3表达越高,预后越差。结论TCGA数据分析显示:EFNA3在肝癌患者高表达,并且EFNA3表达与是肝癌患者预后呈负相关。
Objective To analyze clinical expression of liver cancer EFNA3 based on TCGA database.Methods To analyze relationship between EFNA3 and clinicopathological variables with Wilcoxon signed-rank test,and analyze relationship between EFNA3 expression and overall survival(OS)of liver cancer patients with Kaplan-Meier method.Results①expression of EFNA3 in liver cancer patients was significantly higher than normal people.②expression of EFNA3 in liver cancer and tumor grade(P=0.003),primary lesion size(P=0.006),type of tumor blood vessel(P=0.024),and degree of inflammation of adjacent tissues(P<0.05)showed obvious statistical significance.However,expression of EFNA3 showed no statistical significance with age,gender,lymph node metastasis and distant metastasis.③Kaplan-Meier survival analysis showed expression of EFNA3 was negatively correlated with prognosis of liver cancer patients.The higher expression of EFNA3,the worse prognosis.Conclusion TCGA data analysis shows that EFNA3 is highly expressed in liver cancer patients,and EFNA3 expression is negatively correlated with prognosis of liver cancer patients.
作者
杨沙
谢明
周孟珍
段玉玲
钟明达
刘露
YANG Sha;XIE Ming;ZHOU Meng-zhen;DUAN Yu-ling;ZHONG Ming-da;LIU Lu(Pathology Department,Basic Medical Sciences School,Xiangnan University,Chenzhou,Hunan,423043;Basic Diseases Institute,Xiangnan University,Chenzhou,Hunan,423043;Public Health School,Xiangnan University,Chenzhou,Hunan,423043;Clinical College,Xiangnan University,Chenzhou,Hunan,423043)
出处
《智慧健康》
2020年第21期40-42,共3页
Smart Healthcare
基金
湘南学院科研项目(项目编号:校发[2017]116号-2017XJ36)
